Discovery of entry inhibitors for HIV-1 via a new de novo protein design framework.
about
Molecular recognition of CCR5 by an HIV-1 gp120 V3 loopMolecular recognition of CXCR4 by a dual tropic HIV-1 gp120 V3 loopElucidating a key anti-HIV-1 and cancer-associated axis: the structure of CCL5 (Rantes) in complex with CCR5.Computational Design of Hypothetical New Peptides Based on a Cyclotide Scaffold as HIV gp120 InhibitorForcefield_PTM:Ab InitioCharge and AMBER Forcefield Parameters for Frequently Occurring Post-Translational ModificationsProtein folding and de novo protein design for biotechnological applicationsForcefield_NCAA: ab initio charge parameters to aid in the discovery and design of therapeutic proteins and peptides with unnatural amino acids and their application to complement inhibitors of the compstatin family.Elucidating a key component of cancer metastasis: CXCL12 (SDF-1α) binding to CXCR4.Computational methods for de novo protein design and its applications to the human immunodeficiency virus 1, purine nucleoside phosphorylase, ubiquitin specific protease 7, and histone demethylases.Derivation of ligands for the complement C3a receptor from the C-terminus of C5aNew compstatin peptides containing N-terminal extensions and non-natural amino acids exhibit potent complement inhibition and improved solubility characteristicsAn evolution-based approach to De Novo protein design and case study on Mycobacterium tuberculosis.De novo peptide design and experimental validation of histone methyltransferase inhibitors.De novo design and experimental characterization of ultrashort self-associating peptidesMolecular dynamics in drug design: new generations of compstatin analogs.De novo peptide design with C3a receptor agonist and antagonist activities: theoretical predictions and experimental validation.Drug delivery strategies and systems for HIV/AIDS pre-exposure prophylaxis and treatment.Protein WISDOM: a workbench for in silico de novo design of biomoleculesPeptide fusion inhibitors targeting the HIV-1 gp41: a patent review (2009 - 2014).Rational, computer-enabled peptide drug design: principles, methods, applications and future directions.Novel compstatin family peptides inhibit complement activation by drusen-like deposits in human retinal pigmented epithelial cell cultures.Systematic optimization model and algorithm for binding sequence selection in computational enzyme design.Computational design of helical peptides targeting TNFα.Backbone Dihedral Angle Prediction.Development of peptide inhibitors of HIV transmission.
P2860
Q21559473-666EE0FA-7CFD-4C4F-8FA3-76471D069BB6Q24616040-FABA6E7C-578C-4903-B765-23E7AD404F21Q27309182-C60E5CC8-9B3C-4D7B-BCC8-339E56E69EC4Q28550563-B3EAC60B-C28A-438E-B5B0-72B790084E3CQ30053209-93071B85-1EF2-43EE-8AD8-10A258E1F909Q30355936-F672AA09-CD6D-45A0-968D-46ED4CBD78D4Q30363657-A1CE5B5B-E834-449A-8D20-44E58221DBA4Q30577284-10EF0FF6-CA87-4B9E-803C-AFEDBF06EFAFQ33951142-58760DF5-BDBF-4448-AB1F-747DF07BBE14Q34680953-D018E4B4-80C6-4E28-AD32-D47294F697E6Q35013460-F75EE9B4-E414-448D-8B5A-149160F19E5FQ35034131-8B9CD491-852F-4CD6-8591-D4BBB306638AQ35108673-86A5E373-8085-4E07-8422-EA43EBFA7A6BQ35204571-EF7DC933-F1C7-4098-B0BA-2C853BBD1B4AQ35871691-4CC70D60-2B27-49E2-A198-261BB8C14B0FQ35951590-6F96783A-4B31-4C5B-8E6F-3BF184154DA7Q36934918-ABCFCB9B-5762-4A67-B002-CDF2DDDEC961Q37355358-600E0709-B058-40E7-9831-72C0E0A37183Q38271873-FF0C9FF9-704F-4D97-9ADF-7ADF610CAC4CQ38618616-1407B5D9-BE88-4A59-AA32-A2CB2733C6C4Q41849353-45BE63A8-405A-4BBA-926A-1980D183F525Q43080927-804641BF-8C83-478F-8A13-487FA0379C04Q45013251-627DA7DA-298D-4EE4-81BE-1EC1EEC9EF9DQ45949672-DA84C65A-F45C-4B27-8E8E-4492247C1952Q55317261-0CD18E87-03AF-4AFE-8F13-951BE960AF7C
P2860
Discovery of entry inhibitors for HIV-1 via a new de novo protein design framework.
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Discovery of entry inhibitors for HIV-1 via a new de novo protein design framework.
@ast
Discovery of entry inhibitors for HIV-1 via a new de novo protein design framework.
@en
Discovery of entry inhibitors for HIV-1 via a new de novo protein design framework.
@nl
type
label
Discovery of entry inhibitors for HIV-1 via a new de novo protein design framework.
@ast
Discovery of entry inhibitors for HIV-1 via a new de novo protein design framework.
@en
Discovery of entry inhibitors for HIV-1 via a new de novo protein design framework.
@nl
prefLabel
Discovery of entry inhibitors for HIV-1 via a new de novo protein design framework.
@ast
Discovery of entry inhibitors for HIV-1 via a new de novo protein design framework.
@en
Discovery of entry inhibitors for HIV-1 via a new de novo protein design framework.
@nl
P2093
P2860
P1433
P1476
Discovery of entry inhibitors for HIV-1 via a new de novo protein design framework
@en
P2093
P2860
P304
P356
10.1016/J.BPJ.2010.09.050
P407
P577
2010-11-01T00:00:00Z